UroGen Pharma (URGN) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for UroGen Pharma (URGN) stock.

Latest Upgrades and Downgrades for UroGen Pharma Stock

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Guggenheim	Michael Schmidt	PT Cut	Buy	$58→$56
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$75
—	Guggenheim	Michael Schmitz	PT Raise	Buy	$42→$58
—	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$45→$75
—	TD Cowen	Tara Bancroft	PT Raise	Buy	$50→$60
—	Guggenheim	Brad Canino	PT Raise	Buy	$32→$42
—	Oppenheimer	Leland Gershell	PT Raise	Outperform→Outperformer	$40→$50
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$45
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$45
—	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$40→$45
—	Oppenheimer	Leland Gershell	PT Raise	Outperform	$34→$40
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$33
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$33
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$33
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$33
—	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$40
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$25
—	Piper Sandler	Kelsey Goodwin	Initiate	Overweight	$36
—	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$50→$40

Analyst Ratings News

PRO
Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $56

Guggenheim analyst Michael Schmidt maintains UroGen Pharma (NASDAQ:URGN) with a Buy and lowers the price target from $58 to $56.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $75 price target.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $45 to $75.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

TD Cowen analyst Tara Bancroft maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $50 to $60.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

Guggenheim analyst Brad Canino maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $32 to $42.

Benzinga Newsdesk

UroGen Pharma Ltd

UroGen Pharma (URGN) Stock Price Target 2026

Latest Upgrades and Downgrades for UroGen Pharma Stock

UroGen Pharma (URGN) Stock Price Target 2026

Latest Upgrades and Downgrades for UroGen Pharma Stock

Analyst Ratings News

PRO
Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $56

PRO
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

PRO
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

PRO
TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $56

PRO
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

PRO
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

PRO
TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

UroGen Pharma Ltd

UroGen Pharma (URGN) Stock Price Target 2026

Latest Upgrades and Downgrades for UroGen Pharma Stock

UroGen Pharma (URGN) Stock Price Target 2026

Latest Upgrades and Downgrades for UroGen Pharma Stock

Analyst Ratings News

PROGuggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $56

PROHC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

PROGuggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

PROHC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

PROTD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

PROGuggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

People Also Watch

People Also Watch

Analyst Ratings News

PROGuggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $56

PROHC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

PROGuggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

PROHC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

PROTD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

PROGuggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

PRO
Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $56

PRO
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

PRO
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

PRO
TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42

PRO
Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $56

PRO
HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $75 Price Target

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $58

PRO
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $75

PRO
TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

PRO
Guggenheim Maintains Buy on UroGen Pharma, Raises Price Target to $42